Taxonomic applicability of inflammatory cytokines in adverse outcome pathway (AOP) development

References

• Adeleye, Y., Andersen, M., Clewell, R., Davies, M., Dent, M., Edwards, S., Fowler, P., Malcomber, S., Nicol, B., Scott, A., Scott, S., Sun, B., Westmoreland, C., White, A., Zhang, Q., and Carmichael, P. L. 2015. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. Toxicology 332: 102–111.
   PubMed Web of Science ®Google Scholar
• Angrish, M. M., Madden, M. C., and Pleil, J. D. 2015. Probe molecule (PrM) approach in adverse outcome pathway (AOP) based high-throughput screening (HTS): In vivo discovery for developing in vitro target methods. Chem. Res. Toxicol. 28: 551–559.
   PubMed Web of Science ®Google Scholar
• Arai, K. I., Lee, F., Miyajima, A., Miyatake, S., Arai, N., and Yokota, T. 1990. Cytokines: Coordinators of immune and inflammatory responses. Annu. Rev. Biochem. 59: 783–836.
   PubMed Web of Science ®Google Scholar
• Berg, E. L., Kunkel, E. J., Hytopoulos, E., and Plavec, I. 2006. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J. Pharmacol. Toxicol. Methods 53: 67–74.
   PubMedGoogle Scholar
• Bouman, A., Heineman, M. J., and Faas, M. M. 2005. Sex hormones and the immune response in humans. Hum. Reprod. Update 11: 411–423.
   PubMed Web of Science ®Google Scholar
• Boverhof, D. R., Burgoon, L. D., Tashiro, C., Sharratt, B., Chittim, B., Harkema, J. R., Mendrick, D. L., and Zacharewski, T. R. 2006. Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol. Sci. 94: 398–416.
   PubMed Web of Science ®Google Scholar
• Chen, W., Zhang, Q., Kaplan, B. L., Baker, G. L., and Kaminski, N. E. 2014. Induced T cell cytokine production is enhanced by engineered nanoparticles. Nanotoxicology 8(suppl. 1): 11–23.
   PubMed Web of Science ®Google Scholar
• Chowdhury, F., Williams, A., and Johnson, P. 2009. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J. Immunol. Methods 340: 55–64.
   PubMed Web of Science ®Google Scholar
• Chung, K. F., and Barnes, P. J. 1999. Cytokines in asthma. Thorax 54: 825–857.
   PubMed Web of Science ®Google Scholar
• Csaba, G. 2014. Hormones in the immune system and their possible role. A critical review. Acta Microbiol. Immunol. Hung. 61: 241–260.
   PubMed Web of Science ®Google Scholar
• Dorshkind, K., and Horseman, N. D. 2000. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: Insights from genetic models of hormone and hormone receptor deficiency. Endocr. Rev. 21: 292–312.
   Google Scholar
• Duramad, P., and Holland, N. T. 2011. Biomarkers of immunotoxicity for environmental and public health research. Int. J. Environ. Res. Public Health 8: 1388–1401.
   PubMed Web of Science ®Google Scholar
• Fischer, S. K., Joyce, A., Spengler, M., Yang, T. Y., Zhuang, Y., Fjording, M. S., and Mikulskis, A. 2015. Emerging technologies to increase ligand binding assay sensitivity. Am. Assoc. Pharm. Sci. (AAPS) J. 17: 93–101.
   Google Scholar
• Foster, B., Prussin, C., Liu, F., Whitmire, J. K., and Whitton, J. L. 2007. Detection of intracellular cytokines by flow cytometry. Curr. Protocols Immunol. Chapter 6: Unit 6 24. DOI 10.1002/0471142735.im0624s78
   Google Scholar
• Gangur, V., Birmingham, N. P., and Thanesvorakul, S. 2002. Chemokines in health and disease. Vet. Immunol. Immunopathol. 86: 127–136.
   PubMed Web of Science ®Google Scholar
• Gerard, C., and Rollins, B. J. 2001. Chemokines and disease. Nat. Immunol. 2: 108–115.
   PubMed Web of Science ®Google Scholar
• Goodman, R. B., Strieter, R. M., Martin, D. P., Steinberg, K. P., Milberg, J. A., Maunder, R. J., Kunkel, S. L., Walz, A., Hudson, L. D., and Martin, T. R. 1996. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 154: 602–611.
   PubMed Web of Science ®Google Scholar
• Hofmann, W., Koblinger, L., and Martonen, T. B. 1989. Structural differences between human and rat lungs: implications for Monte Carlo modeling of aerosol deposition. Health Phys. 57(suppl. 1): 41–46; discussion 46–47.
   Google Scholar
• Houck, K. A., Dix, D. J., Judson, R. S., Kavlock, R. J., Yang, J., and Berg, E. L. 2009. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen 14: 1054–1066.
   PubMed Web of Science ®Google Scholar
• Huang, Q., and Riviere, J. E. 2014. The application of allometric scaling principles to predict pharmacokinetic parameters across species. Expert Opin. Drug Metab. Toxicol. 10: 1241–1253.
   PubMed Web of Science ®Google Scholar
• Judson, R., Houck, K., Martin, M., Knudsen, T., Thomas, R. S., Sipes, N., Shah, I., Wambaugh, J., and Crofton, K. 2014. In vitro and modelling approaches to risk assessment from the U.S. Environmental Protection Agency ToxCast programme. Basic Clin. Pharmacol. Toxicol. 115: 69–76.
   PubMed Web of Science ®Google Scholar
• LaLone, C. A., Berninger, J. P., Villeneuve, D. L., and Ankley, G. T. 2014. Leveraging existing data for prioritization of the ecological risks of human and veterinary pharmaceuticals to aquatic organisms. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369: 20140022. http://dx.doi.org/10.1098/rstb.2014.0022
   Google Scholar
• Locatelli, V., Bresciani, E., Tamiazzo, L., and Torsello, A. 2010. Central nervous system-acting drugs influencing hypothalamic–pituitary–adrenal axis function. Endocr. Dev. 17: 108–120.
   PubMedGoogle Scholar
• Luckey, S. W., and Petersen, D. R. 2001. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp. Mol. Pathol. 71: 226–240.
   PubMed Web of Science ®Google Scholar
• Luebke, R. W., Chen, D. H., Dietert, R., Yang, Y., King, M., Luster, M. I., and Immunotoxicology Workgroup. 2006. The comparative immunotoxicity of five selected compounds following developmental or adult exposure. J. Toxicol. Environ. Health B 9: 1–26.
   PubMed Web of Science ®Google Scholar
• Madden, M. C., Stevens, T., Case, M., Schmitt, M., Diaz-Sanchez, D., Bassett, M., Montilla, T. S., Berntsen, J., and Devlin, R. B. 2014. Diesel exhaust modulates ozone-induced lung function decrements in healthy human volunteers. Part. Fibre Toxicol. 11: 37.
   PubMed Web of Science ®Google Scholar
• Martignoni, M., Groothuis, G. M., and de Kanter, R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2: 875–894.
   Google Scholar
• Mestas, J., and Hughes, C. C. 2004. Of mice and not men: Differences between mouse and human immunology. J. Immunol. 172: 2731–2738.
   PubMed Web of Science ®Google Scholar
• Mladineo, I., and Block, B. A. 2010. Expression of cytokines IL-1beta and TNF-alpha in tissues and cysts surrounding Didymocystis wedli (Digenea, Didymozoidae) in the Pacific bluefin tuna (Thunnus orientalis). Fish Shellfish Immunol. 29: 487–493.
   PubMed Web of Science ®Google Scholar
• Mnif, W., Hassine, A. I., Bouaziz, A., Bartegi, A., Thomas, O., and Roig, B. 2011. Effect of endocrine disruptor pesticides: A review. Int. J. Environ. Res. Public Health 8: 2265–2303.
   PubMed Web of Science ®Google Scholar
• Mora, J., Given Chunyk, A., Dysinger, M., Purushothama, S., Ricks, C., Osterlund, K., and Theobald, V. 2014. Next generation ligand binding assays—Review of emerging technologies’ capabilities to enhance throughput and multiplexing. Am. Assoc. Pharm. Sci (AAPS) J. 16: 1175–1184.
   Google Scholar
• Moser, V. C., Stewart, N., Freeborn, D. L., Crooks, J., MacMillan, D. K., Hedge, J. M., Wood, C. E., McMahen, R. L., Strynar, M. J., and Herr, D. W. 2015. Assessment of serum biomarkers in rats after exposure to pesticides of different chemical classes. Toxicol. Appl. Pharmacol. 282: 161–174.
   PubMed Web of Science ®Google Scholar
• Muller, P. Y., and Brennan, F. R. 2009. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin. Pharmacol. Ther. 85: 247–258.
   PubMed Web of Science ®Google Scholar
• Nan, Y. M., Kong, L. B., Ren, W. G., Wang, R. Q., Du, J. H., Li, W. C., Zhao, S. X., Zhang, Y. G., Wu, W. J., Di, H. L., Li, Y., and Yu, J. 2013. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Lipids Health Dis. 12: 11.
   PubMed Web of Science ®Google Scholar
• Perkins, E. J., Chipman, J. K., Edwards, S., Habib, T., Falciani, F., Taylor, R., Van Aggelen, G., Vulpe, C., Antczak, P., and Loguinov, A. 2011. Reverse engineering adverse outcome pathways. Environ. Toxicol. Chem. 30: 22–38.
   PubMed Web of Science ®Google Scholar
• Phadnis-Moghe, A. S., Crawford, R. B., and Kaminski, N. E. 2014. Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) involves altered regulation of B cell lymphoma-6 (BCL-6). Toxicol. Sci. 144: 39–50.
   PubMed Web of Science ®Google Scholar
• Pleil, J. D., Beauchamp, J. D., Miekisch, W., and Funk, W. E. 2015. Adapting biomarker technologies to adverse outcome pathways (AOPs) research: Current thoughts on using in vivo discovery for developing in vitro target methods. J. Breath. Res. 9: 039001.
   PubMed Web of Science ®Google Scholar
• Pleil, J. D., and Sobus, J. R. 2013. Estimating lifetime risk from spot biomarker data and intraclass correlation coefficients (ICC). J. Toxicol. Environ. Health A 76: 747–766.
   PubMed Web of Science ®Google Scholar
• Pleil, J. D., Sobus, J. R., Stiegel, M. A., Hu, D., Oliver, K. D., Olenick, C., Strynar, M., Clark, M., Madden, M. C., and Funk, W. E. 2014. Estimating common parameters of lognormally distributed environmental and biomonitoring data: Harmonizing disparate statistics from publications. J. Toxicol. Environ. Health B 17: 341–368.
   PubMed Web of Science ®Google Scholar
• Pleil, J. D., Williams, M. A., and Sobus, J. R. 2012. Chemical Safety for Sustainability (CSS): Human in vivo biomonitoring data for complementing results from in vitro toxicology—A commentary. Toxicol. Lett. 215: 201–207.
   PubMed Web of Science ®Google Scholar
• Procaccini, C., Pucino, V., De Rosa, V., Marone, G., and Matarese, G. 2014. Neuro-endocrine networks controlling immune system in health and disease. Front. Immunol. 5: 143.
   PubMed Web of Science ®Google Scholar
• Raphael, I., Nalawade, S., Eagar, T. N., and Forsthuber, T. G. 2014. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74: 5–17.
   Google Scholar
• Rappaport, S. M. 2012. Discovering environmental causes of disease. J. Epidemiol. Commun. Health 66: 99–102.
   PubMed Web of Science ®Google Scholar
• Rappaport, S. M., and Smith, M. T. 2010. Epidemiology. Environment and disease risks. Science 330: 460–461.
   PubMed Web of Science ®Google Scholar
• Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., Ferrell, E. P., Randall, J. D., Provuncher, G. K., Walt, D. R., and Duffy, D. C. 2010. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28: 595–599.
   PubMed Web of Science ®Google Scholar
• Romagnani, S. 2000. T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol. 85: 9–18; quiz 18, 21.
   PubMed Web of Science ®Google Scholar
• Shvedova, A. A., Yanamala, N., Murray, A. R., Kisin, E. R., Khaliullin, T., Hatfield, M. K., Tkach, A. V., Krantz, Q. T., Nash, D., King, C., Ian Gilmour, M., and Gavett, S. H. 2013. Oxidative stress, inflammatory biomarkers, and toxicity in mouse lung and liver after inhalation exposure to 100% biodiesel or petroleum diesel emissions. J. Toxicol. Environ. Health A 76: 907–921.
   PubMed Web of Science ®Google Scholar
• Snyder-Talkington, B. N., Qian, Y., Castranova, V., and Guo, N. L. 2012. New perspectives for in vitro risk assessment of multiwalled carbon nanotubes: Application of coculture and bioinformatics. J. Toxicol. Environ. Health B 15: 468–492.
   PubMed Web of Science ®Google Scholar
• Sternberg, E. M. 2001. Neuroendocrine regulation of autoimmune/inflammatory disease. J. Endocrinol. 169: 429–435.
   PubMed Web of Science ®Google Scholar
• Stiegel, M. A., Pleil, J. D., Sobus, J. R., Morgan, M. K., and Madden, M. C. 2015. Analysis of inflammatory cytokines in human blood, breath condensate, and urine using a multiplex immunoassay platform. Biomarkers 20:35–46. doi: 10.3109/1354750X.2014.988646
   Google Scholar
• Stiegel, M. A., Pleil, J. D., Sobus, J. R., and Madden, M. C., 2016. Inflammatory Cytokines and White Blood Cell Counts Response to Environmental Levels of Diesel Exhaust and Ozone Inhalation Exposures, PLoS ONE (submitted).
   Google Scholar
• Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., and Panoskaltsis, N. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018–1028.
   PubMed Web of Science ®Google Scholar
• Tarrant, J. M. 2010. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: Considerations for their use. Toxicol. Sci. 117: 4–16.
   PubMed Web of Science ®Google Scholar
• Villarino, A. V., Kanno, Y., Ferdinand, J. R., and O’Shea, J. J. 2015. Mechanisms of Jak/STAT signaling in immunity and disease. J. Immunol. 194: 21–27.
   PubMed Web of Science ®Google Scholar
• Villeneuve, D. L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T. H., LaLone, C. A., Landesmann, B., Lettieri, T., Munn, S., Nepelska, M., Ottinger, M. A., Vergauwen, L., and Whelan, M. 2014a. Adverse outcome pathway (AOP) development I: Strategies and principles. Toxicol. Sci. 142: 312–320.
   PubMed Web of Science ®Google Scholar
• Villeneuve, D. L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T. H., LaLone, C. A., Landesmann, B., Lettieri, T., Munn, S., Nepelska, M., Ottinger, M. A., Vergauwen, L., and Whelan, M. 2014b. Adverse outcome pathway development II: Best practices. Toxicol. Sci. 142: 321–330.
   PubMed Web of Science ®Google Scholar
• Vos, J. G., and van Loveren, H. 1995. Markers for immunotoxic effects in rodents and man. Toxicol. Lett. 82–83:385–394.
   PubMed Web of Science ®Google Scholar
• Wasinger, V. C., Zeng, M., and Yau, Y. 2013. Current status and advances in quantitative proteomic mass spectrometry. Int. J. Proteomics 2013: 180605.
   PubMedGoogle Scholar
• Wiedermann, F. J., Mayr, A. J., Kaneider, N. C., Fuchs, D., Mutz, N. J., and Schobersberger, W. 2004. Alveolar granulocyte colony-stimulating factor and alpha-chemokines in relation to serum levels, pulmonary neutrophilia, and severity of lung injury in ARDS. Chest 125: 212–219.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2012. Guidance for immunotoxicity risk assessment for chemicals. The Harmonization Project. Geneva, Switzerland: World Heatlth Organization.
   Google Scholar
• Yoon, K., Kwack, S. J., Kim, H. S., and Lee, B. M. 2014. Estrogenic endocrine-disrupting chemicals: Molecular mechanisms of actions on putative human diseases. J. Toxicol. Environ. Health B 17: 127–174.
   PubMed Web of Science ®Google Scholar
• Yoshie, O. 2000. Role of chemokines in trafficking of lymphocytes and dendritic cells. Int. J. Hematol. 72: 399–407.
   PubMed Web of Science ®Google Scholar